<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30175631</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>20</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1473-4877</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>20</Day>                    </PubDate>                </JournalIssue>                <Title>Current medical research and opinion</Title>                <ISOAbbreviation>Curr Med Res Opin</ISOAbbreviation>            </Journal>            <ArticleTitle>Predictors of systemic therapy sequences following a CDK 4/6 inhibitor-based regimen in post-menopausal women with hormone receptor positive, HEGFR-2 negative metastatic breast cancer.</ArticleTitle>            <Pagination>                <MedlinePgn>1-8</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1080/03007995.2018.1519500</ELocationID>            <Abstract>                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To identify systemic treatment in the real-world following treatment with a cyclin-dependent kinase 4/6 inhibitor (CDKi) among post-menopausal women with hormone receptor positive, human epidermal growth factor receptor 2 Negative (HR+/HER2-) metastatic breast cancer (mBC).</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">Post-menopausal women with HR+/HER2- mBC were identified from MarketScan claims databases between January 1, 2012 and October 31, 2017. Eligible mBC patients who received a CDKi-based line of therapy following metastasis diagnosis were selected. A line of therapy ended at the earlier of systemic therapy discontinuation, switch to new treatment, or censoring.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 525 patients that received systemic therapy after a CDKi-based line were included (39.6% transitioned from use of a CDKi-based regimen in first line following metastasis diagnosis to any second line, and 60.4% shifted from a CDKi-based [second, third, or fourth line] to a subsequent line). Of post-CDKi second line regimens (n = 208), 38.0% were endocrine only, 35.6% were chemotherapy-based, 14.4% were everolimus-based, 9.6% were also CDKi-based line, and 2.4% were others. After adjusting for demographic and clinical characteristics, patients transitioning from a CDKi-based line to chemotherapy (vs others) had a trend of being more likely to have recurrent rapidly progressing disease, and were significantly less likely to have the prior CDKi-based line in combination with an AI (both p &lt; .05).</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This population-based study suggests that rapidly progressing disease, metastatic site location, age, and endocrine therapy partner may be predictive of subsequent systemic therapy regimen selection after progression on a CDKi-based line therapy in patients with HR+/HER2- mBC.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Princic</LastName>                    <ForeName>Nicole</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>a IBM Watson Health , Cambridge , MA , USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Aizer</LastName>                    <ForeName>Ayal</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>b Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School , Cambridge , MA , USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tang</LastName>                    <ForeName>Derek H</ForeName>                    <Initials>DH</Initials>                    <AffiliationInfo>                        <Affiliation>c Novartis Pharmaceuticals Corporation , East Hanover , NJ , USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Smith</LastName>                    <ForeName>David M</ForeName>                    <Initials>DM</Initials>                    <AffiliationInfo>                        <Affiliation>a IBM Watson Health , Cambridge , MA , USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Johnson</LastName>                    <ForeName>William</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>a IBM Watson Health , Cambridge , MA , USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bardia</LastName>                    <ForeName>Aditya</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>d Massachusetts General Hospital Cancer Center, Harvard Medical School , Cambridge , MA , USA.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>20</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Curr Med Res Opin</MedlineTA>            <NlmUniqueID>0351014</NlmUniqueID>            <ISSNLinking>0300-7995</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">CDK 4/6 inhibitor</Keyword>            <Keyword MajorTopicYN="N">Metastatic</Keyword>            <Keyword MajorTopicYN="N">Post-menopausal</Keyword>            <Keyword MajorTopicYN="N">Sequences</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>4</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>4</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>4</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30175631</ArticleId>            <ArticleId IdType="doi">10.1080/03007995.2018.1519500</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>